Alice Ho, MD MBA
@AliceHoMD
Followers
248
Following
23
Statuses
19
Radiation Oncologist.#BreastCancer Clinical #Research.Focus on #TNBC, #immunotherapy, postmastectomy RT, complications & reconstruction.#stopasianhate.
Raleigh, NC
Joined November 2016
@guptalabunc @naimurashid @uncbiostat @UNCpublichealth @UNC_Lineberger Congratulations, Naim!!! Well deserved!
0
0
2
0
0
0
RT @AliceHoMD: @guptalabunc @WSJ Agree. The title of the @WSJ article by @Brabbott42 was alarmist ("harsh" RT?) & could potentially misinfo…
0
5
0
@guptalabunc @WSJ Agree. The title of the @WSJ article by @Brabbott42 was alarmist ("harsh" RT?) & could potentially misinform thousands of women who could misunderstand the value of RT. For factual, objective context on PRIME-2, pls read: #DukeRadOnc #dukebreastoncology
0
5
11
RT @guptalabunc: Words matter and the title of this @WSJ article (“harsh radiation”) is poorly informed. For a more informative summary of…
0
3
0
RT @ShannonMacDonMD: My #first tweet- to bring attention to the outdated 18th century laws prohibiting us from providing healthcare to pati���
0
50
0
RT @ABR_Radiology: ABR #volunteer @AliceHoMD has seen breast cancer turn personal through her friend, Jasmine's, treatment. @kodomoboston #…
0
3
0
@HinaSaeedMD @guptalabunc @IanJPereira @CarmeloT2681 @Rad_Nation @Elekta Indeed. Great minds think alike:) Investigators at DFCI @jenbellon will be using their MR sim for treatment planning for the 24Gy arm in the P-RAD study. They will be using MR linac for treatment response as well, I think. #RadOnc #JC
1
0
5
@IanJPereira @CarmeloT2681 @Rad_Nation Totally agree. But we need to shift our mindset as Rad Once, to think more biologically and that requires being in touch with all of the progress in systemic therapy, and thinking about how RT can enhance these therapies. #RadOnc #JC
2
1
7
1
0
4
@HinaSaeedMD @guptalabunc @CarmeloT2681 @Rad_Nation High Risk HR+/HER2- breast ca cohort: Grade 3 OR high genomic assay score (Oncotype Dx RS or Mammaprint). Similar to selection factors for high risk HR+/HER2- in the I-SPY study of durvalumab/olaparib (Pusztai, L AACR 2020). #radONC #JC
0
0
5
@Rad_Nation Pembro/RT in metastatic TNBC: those patients with PDL1+disease and receipt of pembro/RT earlier in dz (1L/2L) appeared to benefit. In several months, we will be launching a anti-PD-1/PARP inhibitor/RT in metastatic TNBC who have progressed through IO or are PDL1-. #RadOnc #JC
0
2
7
@HinaSaeedMD @guptalabunc @Rad_Nation One of the strengths of the P-RAD trial is that it has a control arm of IO/NAC (vs. IO+RT/NAC). The inclusion of NAC in all arms is a confounder (as one can argue that pCR in nodes is due to NAC/IO), however if there is an effect from RT, we will see that. #radonc #JC
1
0
7
@Rad_Nation Hi Everyone! My name is Alice Ho. Breast Rad Onc at MGH. Gaorav Gupta and I, along with a number of my co-authors, are available for the next few hours to discuss immunotherapy and RT for breast cancer as part of the Rad Onc Journal Club #radonc #JC .
1
0
6
@HinaSaeedMD Financial toxicities and patient reported outcomes (carefully selected by experienced patient advocates) will be studied on P-RAD #radonc #JC
0
0
2
@guptalabunc @HinaSaeedMD @CarmeloT2681 @Rad_Nation @HenningWillers @CGrassberger @BreastDocUK @DavidSherMD @rweichselbaum @Sushilberiwal @NatRevClinOncol @CellCellPress @max_diehn We will have the opportunity to answer all of these exciting questions in node-positive TN and HR+/HER2- breast cancer patients on our P-RAD trial, to open shortly #radonc #JC
1
3
11
0
0
0
@subatomicdoc @IanJPereira @ErinGillespieMD @VPrasadMDMPH @oncology_bg Great! Looking forward to it.
0
0
1
@lgotl1230 I'd be interested in this chat, as I've directly seen the benefits (and side effects) of immune therapy in breast ca patients
0
1
1